Please login to the form below
fezolinetant
This page shows the latest fezolinetant news and features for those working in and with pharma, biotech and healthcare.
Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
Astellas Pharma has shared positive 24-week results from a late-stage trial of its non-hormonal menopause drug fezolinetant. ... Fezolinetant works by blocking neurokinin B in the temperature control centre to restore balance and reduce the number and
Latest news
-
Astellas Pharma’s non-hormonal menopause drug granted FDA approval
Astellas Pharma’s Veozah (fezolinetant) has been approved in the US to treat moderate-to-severe vasomotor symptoms (VMS) in menopausal patients.
-
Results for Astellas’ non-hormonal menopause drug published in The Lancet
Improvements were also observed in sleep disturbance, a key secondary endpoint of the study, but statistical significance was not met for fezolinetant dose at 12 weeks. ... The company also reported that additional sleep analyses showed a higher
-
Bayer moves vilaprisan into phase III trials for uterine fibroids
have acquired Ogeda and its phase IIa candidate Fezolinetant.
-
Astellas agrees €800m deal to buy Belgian biotech Ogeda
Astellas is paying 500m upfront and up to 300m extra in clinical and regulatory milestones for Ogeda (formerly known as Euroscreen) and its lead candidate fezolinetant, which has been shown in ... In a phase IIa trial reported in January, fezolinetant
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch - May 2017
Fezolinetant successfully completed a phase 2a study in January in 80 menopausal women. ... In this case $319m is dependent on clinical and regulatory outcomes of fezolinetant.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Dovetail
We help busy pharma teams connect with healthcare professionals and patients to discover insights for better business, better care, and...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
